344 related articles for article (PubMed ID: 26324044)
1. Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.
Lu L; Yu F; Cai L; Debnath AK; Jiang S
Curr Top Med Chem; 2016; 16(10):1074-90. PubMed ID: 26324044
[TBL] [Abstract][Full Text] [Related]
2. Recent Progress in the Development of HIV-1 Entry Inhibitors: From Small Molecules to Potent Anti-HIV Agents.
Suttisintong K; Kaewchangwat N; Thanayupong E; Nerungsi C; Srikun O; Pungpo P
Curr Top Med Chem; 2019; 19(18):1599-1620. PubMed ID: 31424370
[TBL] [Abstract][Full Text] [Related]
3. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
[TBL] [Abstract][Full Text] [Related]
4. Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41.
Pu J; Wang Q; Xu W; Lu L; Jiang S
Viruses; 2019 Aug; 11(8):. PubMed ID: 31374953
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 Entry Inhibitors: A Review of Experimental and Computational Studies.
Mostashari Rad T; Saghaie L; Fassihi A
Chem Biodivers; 2018 Oct; 15(10):e1800159. PubMed ID: 30027572
[TBL] [Abstract][Full Text] [Related]
6. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
Cai L; Gochin M; Liu K
Curr Top Med Chem; 2011 Dec; 11(24):2959-84. PubMed ID: 22044229
[TBL] [Abstract][Full Text] [Related]
7. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
Murray EJ; Leaman DP; Pawa N; Perkins H; Pickford C; Perros M; Zwick MB; Butler SL
J Virol; 2010 Jul; 84(14):7288-99. PubMed ID: 20427524
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound.
Anang S; Richard J; Bourassa C; Goyette G; Chiu TJ; Chen HC; Smith AB; Madani N; Finzi A; Sodroski J
J Virol; 2022 Sep; 96(17):e0063622. PubMed ID: 35980207
[TBL] [Abstract][Full Text] [Related]
9. Strain-Dependent Activation and Inhibition of Human Immunodeficiency Virus Entry by a Specific PF-68742 Stereoisomer.
Zhao C; Princiotto AM; Nguyen HT; Zou S; Zhao ML; Zhang S; Herschhorn A; Farrell M; Pahil K; Melillo B; Sambasivarao SV; Abrams C; Smith AB; Madani N; Sodroski J
J Virol; 2019 Nov; 93(21):. PubMed ID: 31391272
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.
Keller PW; Morrison O; Vassell R; Weiss CD
J Virol; 2018 Aug; 92(16):. PubMed ID: 29875245
[TBL] [Abstract][Full Text] [Related]
11. Small-Molecule CD4 Mimics Containing Mono-cyclohexyl Moieties as HIV Entry Inhibitors.
Ohashi N; Harada S; Mizuguchi T; Irahara Y; Yamada Y; Kotani M; Nomura W; Matsushita S; Yoshimura K; Tamamura H
ChemMedChem; 2016 Apr; 11(8):940-6. PubMed ID: 26891461
[TBL] [Abstract][Full Text] [Related]
12. Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug.
Teixeira C; Gomes JR; Gomes P; Maurel F; Barbault F
Eur J Med Chem; 2011 Apr; 46(4):979-92. PubMed ID: 21345545
[TBL] [Abstract][Full Text] [Related]
13. The Discovery and Development of Oxalamide and Pyrrole Small Molecule Inhibitors of gp120 and HIV Entry - A Review.
Motati DR; Uredi D; Watkins EB
Curr Top Med Chem; 2019; 19(18):1650-1675. PubMed ID: 31424369
[TBL] [Abstract][Full Text] [Related]
14. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
Champagne K; Shishido A; Root MJ
J Biol Chem; 2009 Feb; 284(6):3619-27. PubMed ID: 19073602
[TBL] [Abstract][Full Text] [Related]
15. Development of HIV-1 fusion inhibitors targeting gp41.
Lu K; Asyifah MR; Shao F; Zhang D
Curr Med Chem; 2014 Jun; 21(17):1976-96. PubMed ID: 24350848
[TBL] [Abstract][Full Text] [Related]
16. Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket.
Yu F; Lu L; Du L; Zhu X; Debnath AK; Jiang S
Viruses; 2013 Jan; 5(1):127-49. PubMed ID: 23344560
[TBL] [Abstract][Full Text] [Related]
17. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.
Yi HA; Fochtman BC; Rizzo RC; Jacobs A
Curr HIV Res; 2016; 14(3):283-94. PubMed ID: 26957202
[TBL] [Abstract][Full Text] [Related]
19. A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry.
Herschhorn A; Gu C; Espy N; Richard J; Finzi A; Sodroski JG
Nat Chem Biol; 2014 Oct; 10(10):845-52. PubMed ID: 25174000
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 gp41: mediator of fusion and target for inhibition.
Weiss CD
AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
